Answers are grounded in this paper and cite their sources.
with radiolabeled GCV. Finally, expression of an interleukin-2 variant (IL-2v) from the VV enhanced efficacy. In summary, the addition of HSV-TK.007 to an i.v. oncolytic VV enabled on-demand inhibition of systemic viral replication, skin lesions, environmental shedding, and systemic real-time non-invasive imaging of replication. A phase 1-2 clinical trial was initiated with this i.v. oncolytic VV expressing HSV-TK.007.
No takes yet. Share an insight, caveat, or question.
Maruri-Avidal et al. (2026) studied this question.